Date:11/12/2012

inhabitants of sub-Saharan Africa, and immunocompromised individuals such as organ transplant recipients and AIDS patients. Current treatments for Kaposi sarcoma can inhibit tumor growth but are not able to eliminate KSHV from the host. When the host's immune system weakens, KSHV begins to replicate again, and active tumor growth ensues. New therapeutic approaches are needed. Cannabidiol (CBD), a plant-derived cannabinoid, exhibits promising antitumor effects without inducing psychoactive side effects. CBD is emerging as a novel therapeutic for various disorders, including cancer. In this study, we investigated the effects of CBD both on the infection of endothelial cells (ECs) by KSHV and on the growth and apoptosis of KSHV-infected ECs, an in vitro model for the transformation of normal endothelium to Kaposi sarcoma. While CBD did not affect the efficiency with which KSHV infected ECs, it reduced proliferation and induced apoptosis in those infected by the virus. CBD inhibited the expression of KSHV viral G protein–coupled receptor (vGPCR), its agonist, the chemokine growth-regulated protein α (GRO-α), vascular endothelial growth factor receptor 3 (VEGFR-3), and the VEGFR-3 ligand, vascular endothelial growth factor C (VEGF-C). This suggests a potential mechanism by which CBD exerts its effects on KSHV-infected endothelium and supports the further examination of CBD as a novel targeted agent for the treatment of Kaposi Sarcoma.

About CS-TATI-1

Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through co
'/>"/>

SOURCE Cannabis Science, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Israel Makov Appointed Chairman of Sun Pharma Board
2. Cephasonics Inks Distribution Deal With Tritech To Extend Worldwide Sales Reach Into Israel
3. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
4. Medical Device Study Presents Detailed View of Key Budget and Staffing Metrics for Marketing Groups
5. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
6. Sony Medical Division Teams with Wills Eye Institute to Bring "Expert" Panel of Ophthalmologists to AAO 2012 Convention
7. STD Med Inc. Receives ANVISA Registration for Class III Medical Devices in Brazil
8. Mount Sinai Medical Center 1st in Tri-State Area to Discharge Patient without Human Heart
9. Concord Medical Announces Change to Third Quarter Financial Results Date to November 20, 2012
10. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
11. UBM Canon, lacteur qui fait autorité dans le secteur des technologies médicales, annonce une embauche clé en Allemagne pour compléter son équipe en pleine expansion travaillant sur les solutions médias et marketing